TNF and irritable bowel syndrome: Whether more severe inflammation is required for anti-TNF agents to better exert their effect or CRP and faecal calprotectin merely support the presence of intestinal inflammation in patients otherwise affected by symptoms caused by other conditions (e.g., IBS) remains unclear.